FAQ

Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Questionnaire

Known as: ADCS-ADL, ADL01 
A standardized questionnaire developed by Galasko et al in 1997 as part of the Alzheimer's disease cooperative study, which is used to measure the… (More)

Topic mentions per year

Topic mentions per year

2001-2017
05101520012017

Related topics

Related topics

2 relations
CDISC Questionnaire Category TerminologyClinical Data Interchange Standards Consortium Terminology

Related mentions per year

Related mentions per year

1995-2018
1990200020102020
Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Questionnaire
Clinical Data Interchange Standards Consortium Terminology
CDISC Questionnaire Category Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
BACKGROUND Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 5
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
IMPORTANCE Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
BACKGROUND Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
OBJECTIVE To examine the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, and… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease.
OBJECTIVE This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
CONTEXT Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
BACKGROUND The amyloid-beta peptide Abeta(42) has been implicated in the pathogenesis of Alzheimer's disease (AD). We aimed to… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
OBJECTIVE To evaluate the efficacy and safety of donepezil for severe Alzheimer disease (AD). METHODS Patients with severe AD… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
BACKGROUND The cholinesterase inhibitor donepezil is used to treat mild-to-moderate Alzheimer's disease. Its efficacy in severe… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2006
2006
Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
OBJECTIVE The apolipoprotein E (ApoE) epsilon4 allele is a well-documented genetic risk factor for Alzheimer's disease (AD). Its… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?